-
New Progress in the Hair Loss Prevention Drug Market: JAK Inhibitor Baricitinib Reaches Phase 3 Clinical Primary Endpoint
Market news
PharmaSources.comMarch 26, 2021
Eli Lilly and Company and Incyte jointly announced on Mar. 3, 2021 that baricitinib, an oral JAK inhibitor, met its primary endpoint in Phase 3 clinical trial for the treatment of adult patients with severe alopecia areata (AA).
-
Hyundai Bioscience leads in the repurposing of Niclosamide
Market news
prnasiaApril 09, 2021
A research paper by a South Korean bio tech company that demonstrated the drug repurposing of Niclosamide, an anthelmintic known to have excellent therapeutic efficacy against novel coronavirus infection (COVID-19), was published in the world-renowned ...
-
ImmVira Announces Preclinical and Clinical Data to Be Presented at the 2021 ASCO and AACR Annual Meeting
Market news
prnasiaApril 09, 2021
ImmVira announces that the company will be presenting its first innovative product, MVR-T3011, at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting on June 4-8 2021.
-
CanSinoBIO Announces Approval for its Single-Dose COVID-19 Vaccine Convidecia™ in Chile
Market news
prnasiaApril 09, 2021
CanSino Biologics Inc. announced that the Instituto de Salud Pública de Chile ("ISP") granted emergency use authorization for its Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) ("Ad5-nCoV", trade name: Convidecia™).
-
Global Pharmacovigilance Observatory to aid pharma’s understanding of regulatory decisions
Market news
europeanpharmaceuticalreviewApril 09, 2021
The observatory will collate drug safety data, analyses and decisions into a single source to help pharma identify regional differences in decision-making.
-
Novartis bags EU, UK licences for MS therapy Kesimpta
Market news
pharmatimesApril 09, 2021
Novartis has received green lights from both the European Commission and the UK's Medicines and Healthcare products Regulatory Agency (MHRA) to market its multiple sclerosis (MS) therapy Kesimpta (ofatumumab).
-
Achilles' US IPO closed with proceeds of $175m
Market news
pharmatimesApril 09, 2021
Cancer Research UK spinout Achilles Therapeutics has closed its Initial Public Offering in the US bagging gross proceeds of $175.5 million.
-
Mologic’s COVID-19 Rapid Antigen Self-Test Selected by NIH for RADx Initiative Funding
Market news
americanpharmaceuticalreviewApril 09, 2021
Mologic announced its rapid antigen self-test for COVID-19 has been selected by the Rapid Acceleration of Diagnostics (RADxSM) initiative launched by the U.S. National Institutes of Health (NIH).
-
Acadia Pharmaceuticals Receives Complete Response Letter from U.S. FDA for Supplemental New Drug Application for Pimavanserin for the Treatment of Hallucinations and Delusions Associated with Dementia
Market news
americanpharmaceuticalreviewApril 09, 2021
Acadia Pharmaceuticals Inc. announced that the Company has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding its supplemental New Drug Application (sNDA) for NUPLAZID® (pimavanserin) for the treatment ...
-
ImmunoPrecise Launches TATX-112 Candidate Antibody Program, for the Treatment of Cancer and Alzheimer’s Disease
Market news
americanpharmaceuticalreviewApril 09, 2021
IMMUNOPRECISE ANTIBODIES LTD. a leader in full-service, therapeutic antibody discovery and development, announced that its subsidiary Talem Therapeutics LLC has advanced development of a candidate panel of vetted, novel, therapeutic antibodies ...
Eli Lilly and Company and Incyte jointly announced on Mar. 3, 2021 that baricitinib, an oral JAK inhibitor, met its primary endpoint in Phase 3 clinical trial for the treatment of adult patients with severe alopecia areata (AA).
A research paper by a South Korean bio tech company that demonstrated the drug repurposing of Niclosamide, an anthelmintic known to have excellent therapeutic efficacy against novel coronavirus infection (COVID-19), was published in the world-renowned ...
ImmVira announces that the company will be presenting its first innovative product, MVR-T3011, at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting on June 4-8 2021.
CanSino Biologics Inc. announced that the Instituto de Salud Pública de Chile ("ISP") granted emergency use authorization for its Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) ("Ad5-nCoV", trade name: Convidecia™).
The observatory will collate drug safety data, analyses and decisions into a single source to help pharma identify regional differences in decision-making.
Novartis has received green lights from both the European Commission and the UK's Medicines and Healthcare products Regulatory Agency (MHRA) to market its multiple sclerosis (MS) therapy Kesimpta (ofatumumab).
Cancer Research UK spinout Achilles Therapeutics has closed its Initial Public Offering in the US bagging gross proceeds of $175.5 million.
Mologic announced its rapid antigen self-test for COVID-19 has been selected by the Rapid Acceleration of Diagnostics (RADxSM) initiative launched by the U.S. National Institutes of Health (NIH).
Acadia Pharmaceuticals Inc. announced that the Company has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding its supplemental New Drug Application (sNDA) for NUPLAZID® (pimavanserin) for the treatment ...
IMMUNOPRECISE ANTIBODIES LTD. a leader in full-service, therapeutic antibody discovery and development, announced that its subsidiary Talem Therapeutics LLC has advanced development of a candidate panel of vetted, novel, therapeutic antibodies ...
Pharma Sources Insight 01/2021